Allarity announces FDA granted Fast Track designation to stenoparib

Allarity (ALLR) Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. “We are very pleased that the FDA has granted Fast Track designation to stenoparib,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “This recognition underscores the significant unmet need facing women with advanced ovarian cancer and reflects the potential of stenoparib to meaningfully improve treatment outcomes. We look forward to engaging closely with the FDA as we advance this program.”